People · Operator
Named in public records as an officer, director or promoter · active 2013–2020 · Biotech / Pharma, Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| TwinStrand Biosciences, Inc. | — | Biotech / Pharma | Series C | $85.0M | $132.2M | 2018 |
| Tangen Biosciences, Inc. | — | Biotechnology | Series A | $28.4M | $4.1M | 2016 |
| Enzymatics Inc | — | Other | Seed | $3.8M | $70.4M | 2013 |
Christopher Benoit at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher Benoit on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Chad Waite | 1 | 11 |
| Steve Dow | 1 | 7 |
| Ian Ratcliffe | 1 | 6 |
| Paul Manning | 1 | 6 |
| Soma Somasegar | 1 | 5 |
| Dan Wagner | 1 | 4 |
| Michael Pellini | 1 | 4 |
| Jason Myers | 1 | 4 |
| Jesse Salk | 1 | 3 |
| Christopher McLeod | 1 | 3 |
| Mike Pellini | 1 | 3 |
| Ronnie Andrews | 1 | 2 |
| DAVID CANNER | 1 | 2 |
| Stephen Picone | 1 | 2 |
| Michael Kranda | 1 | 2 |
| Chris Igielski | 1 | 2 |
| Linden Rhoads | 1 | 2 |
| Daniel V. Wagner | 1 | 2 |
| John Davidson | 1 | 2 |
| John Nobile | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.